Literature DB >> 19548033

Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.

Hirohisa Okabe1, Toru Beppu, Hiromitsu Hayashi, Kei Horino, Toshiro Masuda, Hiroyuki Komori, Shinji Ishikawa, Masayuki Watanabe, Hiroshi Takamori, Ken-ichi Iyama, Hideo Baba.   

Abstract

BACKGROUND: Although cumulative evidence supports the fact that stromal myofibroblasts promote tumor progression, the influence of myofibroblasts on intrahepatic cholangiocarcinoma (ICC) is unclear. We hypothesized that hepatic stellate (HS) cells can differentiate into myofibroblasts in ICC stroma and that they promote cancer progression. This study aims to: (1) assess the influence of myofibroblasts on the prognosis of ICC, (2) identify HS cells in ICC stroma, and (3) investigate the interaction between HS cells (LI90 and LX-2) and ICC cells (HuCCT-1 and MEC) in vitro.
METHODS: The association between alpha-smooth muscle actin (alpha-SMA) expression and the prognoses of 46 ICC patients after hepatic resection was evaluated by immunohistochemical analysis. The HS cells in myofibroblasts of ICC were identified (double immunostaining) using antibodies for alpha-SMA, glial fibrillary acidic protein (GFAP), and desmin. The influence of HS cells on the invasion and growth of ICC cells was examined in vitro using a coculture system.
RESULTS: Patients with high alpha-SMA expression exhibited the worse outcomes. Multivariate analyses revealed that high alpha-SMA expression (P = 0.0045) and positivity for lymph-node metastasis were independent prognostic factors. Because desmin- or GFAP-positive cells coexpressing alpha-SMA were observed in the ICC samples, they were considered to be derived from the HS cells. On coculturing with HS cells, a remarkable increase was observed in the invasion and growth of the two ICC cell lines.
CONCLUSIONS: Stromal myofibroblasts may relate to the poor prognoses in ICC patients. HS cells appear to be involved in the progression of ICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548033     DOI: 10.1245/s10434-009-0568-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  Targeting PDGFR-β in Cholangiocarcinoma.

Authors:  Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  Liver Int       Date:  2011-12-02       Impact factor: 5.828

Review 3.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting.

Authors:  Alphonse E Sirica; Gregory J Gores
Journal:  Hepatology       Date:  2014-04-09       Impact factor: 17.425

5.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

6.  Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.

Authors:  Yoko Yashima; Shinpei Sato; Toshihiro Kawai; Takafumi Sugimoto; Takahisa Sato; Miho Kanda; Shuntaro Obi
Journal:  Hepatol Int       Date:  2014-10-01       Impact factor: 6.047

7.  Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.

Authors:  Ling Li; Klaus Piontek; Masaharu Ishida; Michel Fausther; Jonathan A Dranoff; Rongdang Fu; Esteban Mezey; Stephen J Gould; Francis K Fordjour; Stephen J Meltzer; Alphonse E Sirica; Florin M Selaru
Journal:  Hepatology       Date:  2016-08-29       Impact factor: 17.425

Review 8.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment.

Authors:  Dinorah Leyva-Illades; Matthew McMillin; Matthew Quinn; Sharon Demorrow
Journal:  Transl Gastrointest Cancer       Date:  2012

10.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.